Precigen, Inc..
PGEN.US | Research and experimental development on natural sciences and engineering
Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies to improve the lives of patients. The company operates through various segments, including: therapeutics, focused on developing novel therapies for cancer, autoimmune disorders, and infectious diseases; Exemplar ...Show More
Better Health for All
20
Precigen's core business is dedicated to developing gene and cell therapies for serious diseases like cancer and recurrent respiratory papillomatosis (RRP), with clinical trial data consistently showing substantial positive health benefits. For instance, PRGN-2012 demonstrated durable complete responses in RRP patients, with some remaining surgery-free beyond three years,
1
and PRGN-3005 showed a tumor burden decrease in 67% of advanced ovarian cancer patients.
2
The company has no revenue from products with established negative health outcomes. Its therapies in clinical trials have demonstrated an outstanding safety record, with no dose-limiting toxicities or neurotoxicity reported for multiple candidates,
3
and adverse events generally not exceeding Grade 2.
4
Precigen significantly invests in health innovation, with R&D expenses increasing by 9% to $53.070 million in 2024,
5
primarily for confirmatory trials and manufacturing of PRGN-2012.
6
The company has an Expanded Access Policy from April 2022,
7
outlining a process for evaluating benefit-risk ratios for individual patients seeking investigational therapies outside of clinical trials, with requests acknowledged within 5 business days.
8
No specific information is available regarding the company's approach to patent flexibility for its pharmaceutical products.
Fair Money & Economic Opportunity
0
No evidence available to assess Precigen, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
-20
Precigen, Inc. received an overall employee review sentiment of 2.3 out of 5 stars, which translates to approximately 46 out of 100 for worker engagement.
1
This score falls between the rubric's thresholds for 45% (tier -50) and 50% (tier -40). Following the rule to choose the tier closer to zero, the score is -40. No specific quantitative data was found for living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
2
Qualitative feedback from reviews indicated concerns about job security, layoffs, management, and culture, but these were not accompanied by specific metrics required for scoring other KPIs.
3
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend was found in the provided articles.
1
Honest & Fair Business
0
No specific, quantifiable evidence was found in the provided articles to score any of the KPIs against the rubric's defined thresholds and timeframes. While a $2.6 million civil penalty was levied against Intrexon (Precigen's predecessor) by the SEC in September 2020 for misleading statements.
1
This falls outside the 'past three years' window required for the regulatory_fines_3y KPI. Additionally, a securities litigation case alleging false and misleading statements was settled in November 2023.
2
But no specific financial restatement numbers or ESG controversy index scores were provided.
Kind to Animals
-40
Precigen Exemplar's facilities are fully accredited by AAALAC International, PHS assured, FDA compliant, and USDA approved,
1
indicating that 100% of its animal-related operations hold recognized humane certifications. However, the company relies on in vivo studies in animal species for safety and quality assessments
2
and develops animal models for pre-clinical research,
3
with no mention of employing non-animal testing methods. Precigen Exemplar states a commitment to humane use and care of research animals
4
and compliance with the Animal Welfare Act,
5
but an incident in January where two pigs died during transport led to a report of noncompliance and required corrective actions,
6
indicating inconsistent enforcement. The company has developed over twenty genetically engineered research models since 2008,
7
with a project in June 2021 aiming to have animals available in late 2022,
8
indicating ongoing animal use. The company's use of gene-edited swine models for human disease research,
9
without explicit details on enrichment or space allocation, suggests standard industry practices. Precigen Exemplar is a member of an industry consortium working on animal-free testing methods,
10
but the extent of its contributions is minimal.
No War, No Weapons
0
The provided articles describe Precigen, Inc. as a biotechnology company focused on developing gene and cell therapies, gene-edited swine for biomedical research, and bovine reproductive technologies.
1
The company's technologies are stated to be applicable across diverse end markets including healthcare, food, energy, and environmental sciences.
2
Lobbying activities are categorized under 'Pharmaceuticals/Health Products'.
3
No specific, concrete data points were found in the articles regarding any involvement in arms manufacturing, military contracts, dual-use technologies with military applications, sales to embargoed regimes, peacebuilding investments, or any other activities directly related to the 'No War, No Weapons' value. Therefore, all KPIs for this value must be omitted due to lack of explicit evidence.
Planet-Friendly Business
0
No information regarding Precigen, Inc.'s planet-friendly business practices, environmental performance, or sustainability initiatives was found in the provided articles. The articles focused on general biotechnology industry news and the financial results of other companies.
Respect for Cultures & Communities
0
No evidence available to assess Precigen, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
-10
Precigen has not suffered any material Personal Data Breaches or other Security Incidents in the past five years, nor has it received any related material claims or investigations during this period.
1
The company maintains a commercially reasonable, enterprise-wide privacy and information security program, including plans and procedures for incident detection and response.
2
It conducts commercially reasonable privacy and security audits and penetration tests at reasonable intervals on all systems handling sensitive information, consistent with industry practices.
3
The company's Code of Business Conduct and Ethics, last revised November 8, 2020, prohibits employees from unauthorized disclosure or use of confidential company information.
4
Precigen states it is committed to complying with all applicable data privacy laws and has implemented policies and procedures for personnel training that are reasonable and customary in the pharmaceutical industry to ensure compliance with relevant laws, including Data Protection Laws.
5
The company's privacy policy, last updated August 8, 2025, indicates it collects only necessary personal data and retains it to fulfill collection purposes or as required by law.
6
Users can manage cookies through browser or mobile settings.
7
The company's Security Program includes plans, policies, and procedures for encryption and data back-up.
8
It also includes plans, policies, and procedures for Systems access controls and incident detection.
9
The company conducts commercially reasonable privacy and security audits and penetration tests at reasonable intervals on all Systems that maintain, store, access, or process Sensitive Information.
10
It also conducts commercially reasonable privacy and data security diligence on all applicable service providers.
11
Zero Waste & Sustainable Products
0
No specific, quantifiable data for Precigen, Inc. (PGEN.US) regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability scores, waste audit frequency, zero-waste certifications, waste disposal violations, material efficiency, packaging-to-product ratios, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles. The articles discuss general industry trends and challenges in biopharmaceutical and cell and gene therapy manufacturing, such as plastic waste from single-use technologies and the need for waste reduction strategies, but do not provide company-specific performance metrics for PGEN.US.